Outcomes of patients with cytomegalovirus viremia at the time of liver transplantation

Liver Transpl. 2014 Sep;20(9):1029-33. doi: 10.1002/lt.23915. Epub 2014 Aug 4.

Abstract

Cytomegalovirus (CMV) infection has been associated with poor outcomes after liver transplantation. Whether it is safe to perform transplantation for patients with active CMV viremia is not known. Here we report the outcomes of 6 patients with CMV viremia immediately before or at the time of liver transplantation. Data from these patients indicate that CMV can be adequately controlled with antiviral therapy, although patients appear to be at higher risk for indirect effects of CMV such as other opportunistic infections and liver allograft dysfunction.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents / therapeutic use
  • Cytomegalovirus Infections / blood
  • Cytomegalovirus Infections / complications*
  • Cytomegalovirus Infections / diagnosis
  • Cytomegalovirus Infections / drug therapy
  • End Stage Liver Disease / complications
  • End Stage Liver Disease / diagnosis
  • End Stage Liver Disease / surgery*
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Liver Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Minnesota
  • Postoperative Complications / etiology
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Viral Load
  • Young Adult

Substances

  • Antiviral Agents
  • Immunosuppressive Agents